Orblid (bevacizumab)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- bevacizumab
- Company
- Laboratoires Delbert
- Status
- Application withdrawn
- Therapeutic area
- Telangiectasia, Hereditary Hemorrhagic
- Designations
- Orphan
- Application
- EMEA/H/C/006392
- ATC
- L01FG01
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with hereditary haemorrhagic telangiectasia
Regulatory milestones
Thu 21 May 2026🇪🇺 Application withdrawn (EU)
Orblid (bevacizumab): EU application withdrawn
Same substance in other markets
- 🇪🇺 Mvasi Authorised · Amgen Europe B.V.
- 🇪🇺 Aybintio Authorised · Samsung Bioepis NL B.V.
- 🇪🇺 Lytenava Authorised · Outlook Therapeutics NL B. V.
- 🇪🇺 Abevmy Authorised · Biosimilar Collaborations Ireland Limited
- 🇪🇺 Zirabev Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Avzivi Authorised · FGK Representative Service GmbH
- 🇪🇺 Alymsys Authorised · Mabxience Research SL
- 🇪🇺 Oyavas Authorised · STADA Arzneimittel AG
- 🇪🇺 Vegzelma Authorised · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Avastin Authorised · Roche Registration GmbH
- 🇪🇺 Onbevzi Withdrawn · Samsung Bioepis NL B.V.
- 🇪🇺 Ipique Refused · Rotterdam Biologics B.V.
Follow Orblid
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.